Press Releases
Stay updated on the latest Vistagen News and get the details about important events, public financial reports, and our product pipeline updates.
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/22/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today a peer-reviewed publication
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/01/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that its largest
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/27/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today the peer-reviewed
Mar 29, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/29/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the European Patent
Mar 08, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/08/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system ( CNS ) disorders, announced today that Shawn Singh, Chief
Feb 13, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/13/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN) , a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system ( CNS ) disorders, today reported financial results for the
Presentation with live webcast on Tuesday, January 10th at 3:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Jan. 5, 2017 /PRNewswire/ -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central
Dec 14, 2016
VistaGen to receive upfront payment of $1.25M SOUTH SAN FRANCISCO, Calif., Dec. 14, 2016 /PRNewswire/ -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system ( CNS )
- Presentation with Live Audio Webcast on Wednesday, December 7th at 12:30 p.m. PT - SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 /PRNewswire/ -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and
Nov 14, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 /PRNewswire/ -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system ( CNS ) disorders, today reported financial results for
